Angiotensin-Converting Enzyme Inhibitors and Risk of Esophageal and Gastric Cancer: A Nested Case-Control Study
- 31 October 2007
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 5 (10), 1160-1166.e1
- https://doi.org/10.1016/j.cgh.2007.08.005
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Manipulating the angiotensin system – new approaches to the treatment of solid tumoursExpert Opinion on Biological Therapy, 2006
- Cancer, inflammation and the AT1 and AT2 receptorsJournal of Inflammation, 2004
- Role of host angiotensin II type 1 receptor in tumor angiogenesis and growthJournal of Clinical Investigation, 2003
- Validity of the General Practice Research DatabasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Angiogenesis inhibitors in clinical development for lung cancerSeminars in Oncology, 2002
- Angiotensin-converting enzyme inhibitors and the risk of cancerCancer, 2001
- Cancer burden in the year 2000. The global pictureEuropean Journal Of Cancer, 2001
- Relation between drug treatment and cancer In hypertenslves in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trialThe Lancet, 2001
- Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?The Lancet, 1998
- Use of the UK General Practice Research Database for pharmacoepidemiologyBritish Journal of Clinical Pharmacology, 1998